Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation

A. Brioli, G. Perrone, F. Patriarca, A. Pezzi, F. Nobile, F. Ballerini, M. R. Motta, S. Ronconi, P. Tacchetti, L. Catalano, B. A. Zannetti, S. Rizzi, S. Volpe, E. Zamagni, A. M. Liberati, K. Mancuso, M. Boccadoro, F. E. Davies, G. J. Morgan, A. PalumboM. Cavo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Incorporation of novel agents into auto-SCT for patients with multiple myeloma has led to improvement in their outcomes. However, the effects of new drugs, either single or combined, on PBSC mobilization have not been fully evaluated, particularly in phase 3 clinical studies. We analyzed the impact of two novel agent-based induction treatments in patients enrolled in the GIMEMA MMY-3006 study comparing bortezomib, thalidomide and dexamethasone (VTD) versus thalidomide and dexamethasone (TD) in preparation for double auto-SCT. Results showed that a short-term induction therapy with VTD did not adversely affect CD34 + cell yields as compared with TD (9.75 vs 10.76 × 10 6 CD34 + cells/kg, P=0.220). For poor mobilizers (6 CD34 + cells/kg), 5-year rates of time to progression (TTP), progression-free survival (PFS) and overall survival (OS) were significantly shorter than for successful mobilizers (TTP:17 vs 48%, P+ cells. The number of collected PBSCs predicted better outcomes after auto-SCT and VTD overcame the negative impact of a poor stem cell mobilization.

Original languageEnglish
Pages (from-to)673-678
Number of pages6
JournalBone Marrow Transplantation
Volume50
Issue number5
DOIs
Publication statusPublished - May 8 2015

Fingerprint

Autologous Transplantation
Multiple Myeloma
Thalidomide
Dexamethasone
Hematopoietic Stem Cell Mobilization
Disease-Free Survival
Survival
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Transplantation
  • Medicine(all)

Cite this

Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. / Brioli, A.; Perrone, G.; Patriarca, F.; Pezzi, A.; Nobile, F.; Ballerini, F.; Motta, M. R.; Ronconi, S.; Tacchetti, P.; Catalano, L.; Zannetti, B. A.; Rizzi, S.; Volpe, S.; Zamagni, E.; Liberati, A. M.; Mancuso, K.; Boccadoro, M.; Davies, F. E.; Morgan, G. J.; Palumbo, A.; Cavo, M.

In: Bone Marrow Transplantation, Vol. 50, No. 5, 08.05.2015, p. 673-678.

Research output: Contribution to journalArticle

Brioli, A, Perrone, G, Patriarca, F, Pezzi, A, Nobile, F, Ballerini, F, Motta, MR, Ronconi, S, Tacchetti, P, Catalano, L, Zannetti, BA, Rizzi, S, Volpe, S, Zamagni, E, Liberati, AM, Mancuso, K, Boccadoro, M, Davies, FE, Morgan, GJ, Palumbo, A & Cavo, M 2015, 'Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation', Bone Marrow Transplantation, vol. 50, no. 5, pp. 673-678. https://doi.org/10.1038/bmt.2014.322
Brioli, A. ; Perrone, G. ; Patriarca, F. ; Pezzi, A. ; Nobile, F. ; Ballerini, F. ; Motta, M. R. ; Ronconi, S. ; Tacchetti, P. ; Catalano, L. ; Zannetti, B. A. ; Rizzi, S. ; Volpe, S. ; Zamagni, E. ; Liberati, A. M. ; Mancuso, K. ; Boccadoro, M. ; Davies, F. E. ; Morgan, G. J. ; Palumbo, A. ; Cavo, M. / Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. In: Bone Marrow Transplantation. 2015 ; Vol. 50, No. 5. pp. 673-678.
@article{43923d1f237a49aaa591a031b997a899,
title = "Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation",
abstract = "Incorporation of novel agents into auto-SCT for patients with multiple myeloma has led to improvement in their outcomes. However, the effects of new drugs, either single or combined, on PBSC mobilization have not been fully evaluated, particularly in phase 3 clinical studies. We analyzed the impact of two novel agent-based induction treatments in patients enrolled in the GIMEMA MMY-3006 study comparing bortezomib, thalidomide and dexamethasone (VTD) versus thalidomide and dexamethasone (TD) in preparation for double auto-SCT. Results showed that a short-term induction therapy with VTD did not adversely affect CD34 + cell yields as compared with TD (9.75 vs 10.76 × 10 6 CD34 + cells/kg, P=0.220). For poor mobilizers (6 CD34 + cells/kg), 5-year rates of time to progression (TTP), progression-free survival (PFS) and overall survival (OS) were significantly shorter than for successful mobilizers (TTP:17 vs 48{\%}, P+ cells. The number of collected PBSCs predicted better outcomes after auto-SCT and VTD overcame the negative impact of a poor stem cell mobilization.",
author = "A. Brioli and G. Perrone and F. Patriarca and A. Pezzi and F. Nobile and F. Ballerini and Motta, {M. R.} and S. Ronconi and P. Tacchetti and L. Catalano and Zannetti, {B. A.} and S. Rizzi and S. Volpe and E. Zamagni and Liberati, {A. M.} and K. Mancuso and M. Boccadoro and Davies, {F. E.} and Morgan, {G. J.} and A. Palumbo and M. Cavo",
year = "2015",
month = "5",
day = "8",
doi = "10.1038/bmt.2014.322",
language = "English",
volume = "50",
pages = "673--678",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation

AU - Brioli, A.

AU - Perrone, G.

AU - Patriarca, F.

AU - Pezzi, A.

AU - Nobile, F.

AU - Ballerini, F.

AU - Motta, M. R.

AU - Ronconi, S.

AU - Tacchetti, P.

AU - Catalano, L.

AU - Zannetti, B. A.

AU - Rizzi, S.

AU - Volpe, S.

AU - Zamagni, E.

AU - Liberati, A. M.

AU - Mancuso, K.

AU - Boccadoro, M.

AU - Davies, F. E.

AU - Morgan, G. J.

AU - Palumbo, A.

AU - Cavo, M.

PY - 2015/5/8

Y1 - 2015/5/8

N2 - Incorporation of novel agents into auto-SCT for patients with multiple myeloma has led to improvement in their outcomes. However, the effects of new drugs, either single or combined, on PBSC mobilization have not been fully evaluated, particularly in phase 3 clinical studies. We analyzed the impact of two novel agent-based induction treatments in patients enrolled in the GIMEMA MMY-3006 study comparing bortezomib, thalidomide and dexamethasone (VTD) versus thalidomide and dexamethasone (TD) in preparation for double auto-SCT. Results showed that a short-term induction therapy with VTD did not adversely affect CD34 + cell yields as compared with TD (9.75 vs 10.76 × 10 6 CD34 + cells/kg, P=0.220). For poor mobilizers (6 CD34 + cells/kg), 5-year rates of time to progression (TTP), progression-free survival (PFS) and overall survival (OS) were significantly shorter than for successful mobilizers (TTP:17 vs 48%, P+ cells. The number of collected PBSCs predicted better outcomes after auto-SCT and VTD overcame the negative impact of a poor stem cell mobilization.

AB - Incorporation of novel agents into auto-SCT for patients with multiple myeloma has led to improvement in their outcomes. However, the effects of new drugs, either single or combined, on PBSC mobilization have not been fully evaluated, particularly in phase 3 clinical studies. We analyzed the impact of two novel agent-based induction treatments in patients enrolled in the GIMEMA MMY-3006 study comparing bortezomib, thalidomide and dexamethasone (VTD) versus thalidomide and dexamethasone (TD) in preparation for double auto-SCT. Results showed that a short-term induction therapy with VTD did not adversely affect CD34 + cell yields as compared with TD (9.75 vs 10.76 × 10 6 CD34 + cells/kg, P=0.220). For poor mobilizers (6 CD34 + cells/kg), 5-year rates of time to progression (TTP), progression-free survival (PFS) and overall survival (OS) were significantly shorter than for successful mobilizers (TTP:17 vs 48%, P+ cells. The number of collected PBSCs predicted better outcomes after auto-SCT and VTD overcame the negative impact of a poor stem cell mobilization.

UR - http://www.scopus.com/inward/record.url?scp=84928924087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928924087&partnerID=8YFLogxK

U2 - 10.1038/bmt.2014.322

DO - 10.1038/bmt.2014.322

M3 - Article

C2 - 25642764

AN - SCOPUS:84928924087

VL - 50

SP - 673

EP - 678

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -